◆ NeutralLLYNVO
Eli Lilly's Next Big Growth Opportunity Could Be Hiding in Plain Sight
The Motley Fool·
Eli Lilly's weight-loss drug Zepbound showed strong clinical trial results in adolescents aged 12-17, with participants losing an average of 40 pounds and experiencing improved cardiovascular health markers. This could open a significant new market of over 5 million U.S. patients, potentially generating $6.5 billion in additional annual revenue. The company is also testing Zepbound in younger children aged 6-11, further expanding its addressable market despite competition from Novo Nordisk's Wegovy.
Read Full Article at The Motley Fool →